With a market capitalization (market cap) of $1.98B — a measure of how much the company is worth — Taysha Gene Therapies, Inc. is the 2117th most valuable company in Healthcare as of August 18, 2026. Shares trade at $6.19, down +0.32% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Visit websiteAs of August 18, 2026, Taysha Gene Therapies, Inc. (TSHA) is worth $1.98B — this is its market capitalization, the total value of all its outstanding shares.
Taysha Gene Therapies, Inc.’s market cap is $1.98B, which ranks it #2117 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Taysha Gene Therapies, Inc. (TSHA) shares trade at $6.19, down 0.32% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025